Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in severe steroid-dependent asthma
NL-OMON44861Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Dupilumab + background controller therapy with Placebo + background controller therapy (2 arms). Primary endpoint: Percentage change in oral corticosteroid dose while maintaining asthma control. Started Mar 2016; status: active, not recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON44861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44861.